Searching for your content...
In-Language News
Contact Us
888-776-0942 from 8 AM - 10 PM ET
Mallinckrodt plc (NYSE American: MNK), a global specialty pharmaceutical company, today announced the presentation of results from two clinical...
Advanced Launch of Terlivaz® with Rapid and Successful Uptake in Hospital Formulary Access and Continued Medical Community Interest Reports First...
Mallinckrodt plc (NYSE American: MNK), a global specialty pharmaceutical company, is pleased to announce it has received an award from the National...
Mallinckrodt plc (NYSE American: MNK), a global specialty pharmaceutical company, today announced that it will report first quarter 2023 earnings...
Mallinckrodt plc (NYSE American: MNK), a global specialty pharmaceutical company, today announced that two scientific abstracts on the clinical and...
Mallinckrodt plc (NYSE American: MNK), a global specialty pharmaceutical company, today announced that an abstract highlighting results from a...
Mallinckrodt plc, (NYSE American: MNK) ("Mallinckrodt" tai "Yhtiö"), maailmanlaajuinen erikoislääkeyhtiö, ilmoitti tänään, että Japanin kansallinen...
Mallinckrodt plc, (NYSE American:MNK) ("Mallinckrodt" eller "Selskapet"), et globalt farmasiselskap, har i dag kunngjort at Japans nasjonale...
Mallinckrodt plc, (NYSE American: MNK) ("Mallinckrodt" eller "Virksomheden"), en global medicinalvirksomhed inden for speciallægemidler, kan i dag...
A Mallinckrodt plc, (NYSE American: MNK) ("Mallinckrodt" ou a "empresa"), uma empresa farmacêutica global especializada, anunciou hoje que o sistema...
Mallinckrodt plc, (NYSE American: MNK) ("Mallinckrodt" or the "Company"), a global specialty pharmaceutical company, today announced that Japan's...
Mallinckrodt plc,(NYSE American: MNK) („Mallinckrodt" oder das „Unternehmen"),ein weltweit tätiges Spezialpharmaunternehmen, gab heute bekannt, dass...
Mallinckrodt plc, (NYSE American: MNK, "Mallinckrodt" o la "azienda"), azienda farmaceutica specializzata a livello globale, ha annunciato oggi che...
Mallinckrodt plc, (NYSE American: MNK) ("Mallinckrodt" o la "Compañía"), una una compañía farmacéutica especializada global, ha anunciado hoy que el...
Mallinckrodt plc, (NYSE American : MNK) (« Mallinckrodt » ou la « Société »), une société pharmaceutique internationale spécialisée, a annoncé...
Firma Mallinckrodt plc, (NYSE American: MNK) („Mallinckrodt" lub „spółka"), międzynarodowa specjalistyczna spółka farmaceutyczna, poinformowała...
Mallinckrodt plc (NYSE American: MNK) ("Mallinckrodt" or the "Company"), a global specialty pharmaceutical company, today reported results for the...
Mallinckrodt plc (NYSE American: MNK), a global specialty pharmaceutical company, today announced that Siggi Olafsson, President and Chief Executive...
Mallinckrodt plc (NYSE American: MNK), a global specialty pharmaceutical company, today announced that it will report fourth quarter 2022 earnings...
Mallinckrodt plc (NYSE American: MNK), a global specialty pharmaceutical company, today announced the presentation of results from a retrospective...
Mallinckrodt plc (NYSE American: MNK) ("Mallinckrodt" or the "Company"), a global specialty pharmaceutical company, today announced that Dr. Peter...
Mallinckrodt plc (NYSE American: MNK), a global specialty pharmaceutical company, today announced the recipient of 2022's Advancing Extracorporeal...
Mallinckrodt plc (NYSE American: MNK), a global specialty pharmaceutical company, today announced that seven scientific abstracts on clinical and...
Join PR Newswire for Journalists to access all of the free services designated to make your job easier.
In need of subject matter experts for your story? Submit a free ProfNet request and find the sources you need.